Windmil_rgb_large.png
WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Marrow from Patients with Gliomas to Develop Marrow Infiltrating Lymphocytes (MILs™)
October 15, 2019 07:00 ET | WindMIL Therapeutics
BALTIMORE and PHILADELPHIA and IRVINE, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics and the University of California, Irvine (UCI) today announced that the first patients have...
Windmil_rgb_large.png
WindMIL Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa
September 30, 2019 07:00 ET | WindMIL Therapeutics
BALTIMORE, Md. and PHILADELPHIA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy,...
WindMIL Therapeutics Appoints Urvashi Patel, PhD, as Vice President of Regulatory and Quality Systems
September 09, 2019 07:00 ET | WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Sept. 09, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has...
Full Color CMYK.jpg
WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)
July 09, 2019 07:00 ET | WindMIL Therapeutics
BALTIMORE and PHILADELPHIA and ANN ARBOR, Mich., July 09, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and the University of Michigan Rogel Cancer Center today announced that the first...
Full Color CMYK.jpg
WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer
June 25, 2019 07:00 ET | WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, June 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced...
WindMIL Therapeutics Appoints Donald J. Hayden, Jr., as CEO
April 25, 2019 07:00 ET | WindMIL Therapeutics
BALTIMORE, Md., April 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
WindMIL Therapeutics Announces Promotions to Newly Created Leadership Roles as Part of Continued Growth
April 17, 2019 07:00 ET | WindMIL Therapeutics
BALTIMORE, April 17, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the promotions...
WindMIL Therapeutics Appoints Sanjin Zvonić, PhD, as Vice President of Process Science and Manufacturing
March 25, 2019 08:00 ET | WindMIL Therapeutics
BALTIMORE, March 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
Full Color CMYK.jpg
WindMIL Therapeutics Expands Leadership Team and Opens Office in Philadelphia
December 20, 2018 07:00 ET | WindMIL Therapeutics
BALTIMORE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
Full Color CMYK.jpg
WindMIL Therapeutics Announces Preclinical Data Demonstrating Marrow-Infiltrating Lymphocytes’ Potential as CAR-Modified T Cell Therapy Platform
December 03, 2018 07:00 ET | WindMIL Therapeutics
BALTIMORE, Dec. 03, 2018 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, yesterday announced...